[go: up one dir, main page]

AU2001265187A1 - Chimeric viral vectors for gene therapy - Google Patents

Chimeric viral vectors for gene therapy

Info

Publication number
AU2001265187A1
AU2001265187A1 AU2001265187A AU6518701A AU2001265187A1 AU 2001265187 A1 AU2001265187 A1 AU 2001265187A1 AU 2001265187 A AU2001265187 A AU 2001265187A AU 6518701 A AU6518701 A AU 6518701A AU 2001265187 A1 AU2001265187 A1 AU 2001265187A1
Authority
AU
Australia
Prior art keywords
gene therapy
viral vectors
chimeric viral
chimeric
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265187A
Inventor
Estuardo Aguilar-Cordova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2001265187A1 publication Critical patent/AU2001265187A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001265187A 2000-05-30 2001-05-30 Chimeric viral vectors for gene therapy Abandoned AU2001265187A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20784500P 2000-05-30 2000-05-30
US60207845 2000-05-30
PCT/US2001/017453 WO2001091802A1 (en) 2000-05-30 2001-05-30 Chimeric viral vectors for gene therapy

Publications (1)

Publication Number Publication Date
AU2001265187A1 true AU2001265187A1 (en) 2001-12-11

Family

ID=22772212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265187A Abandoned AU2001265187A1 (en) 2000-05-30 2001-05-30 Chimeric viral vectors for gene therapy

Country Status (3)

Country Link
US (1) US20060057553A1 (en)
AU (1) AU2001265187A1 (en)
WO (1) WO2001091802A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0973928T3 (en) 1997-03-11 2010-08-09 Univ Minnesota DNA-based transposon system for introducing nucleic acid into DNA in a cell
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
GB2355459B (en) 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
BRPI1013771A2 (en) * 2009-04-13 2016-04-05 Apceth Gmbh & Co Kg "Designed mesenchymal stem cells and method of using them to treat tumors."
CN117205331A (en) 2011-04-29 2023-12-12 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers for reducing antibody responses
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
CN110639024A (en) 2013-05-03 2020-01-03 西莱克塔生物科技公司 Methods and compositions for enhancing CD4+ regulatory T cells
US10167454B2 (en) * 2014-03-09 2019-01-01 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
GB2526867A (en) 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
BR112017001601A2 (en) 2014-09-07 2017-11-21 Selecta Biosciences Inc methods and compositions for attenuating immune responses of the modulating antiviral transfer vector of gene expression
US10376549B2 (en) * 2015-01-20 2019-08-13 Adcure Biotechnologies, Llc. Detargeted adenovirus variants and related methods
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
EP3380604B1 (en) * 2015-11-24 2022-12-28 GlaxoSmithKline Intellectual Property Development Limited Stable cell lines for retroviral production
KR102067352B1 (en) 2015-11-24 2020-01-16 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Transient Transfection Methods for Retrovirus Production
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
ES2911448T3 (en) 2016-03-09 2022-05-19 American Gene Tech Int Inc Combined Vectors and Methods for Cancer Treatment
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
IL284348B2 (en) 2016-07-08 2025-06-01 American Gene Tech Int Inc Pre-HIV vaccination and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
BR112019002771A2 (en) 2016-08-12 2019-05-14 Oxitec Ltd doublesex union control module polynucleotide, gene expression system, expression vector plasmid, genetically engineered insect, methods for producing genetically engineered insects, for selectively cultivating genetically engineered male insects, for reducing a wild insect population, for breeding a transgenic aedes aegypti mosquito and to detect the presence of a dna molecule, chromosomal target site of aedes aegypti, genetically engineered aedes aegypti mosquito, dna molecule, and dna detection kit.
CN110325203A (en) 2017-01-07 2019-10-11 西莱克塔生物科技公司 Medelling with the immunosuppressor of synthesis nano-carrier coupling is administered
MX2019010757A (en) 2017-03-11 2020-01-20 Selecta Biosciences Inc METHODS AND COMPOSITIONS RELATED TO THE COMBINED TREATMENT WITH ANTI-INFLAMMATORY AND SYNTHETIC NANPORTERS THAT INCLUDE AN IMMUNOSUPPRESSOR.
KR102737836B1 (en) 2017-04-03 2024-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 Compositions and methods for treating phenylketonuria
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
AR117409A1 (en) 2018-03-29 2021-08-04 Oxitec Ltd SELF-LIMITING NIGHTS
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
US20220090132A1 (en) * 2019-01-06 2022-03-24 Abintus Bio, Inc. Car t cell methods and constructs
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CN114901297A (en) * 2019-10-16 2022-08-12 卡利威尔免疫治疗公司 Producer virus for in situ generation of retroviruses
KR20230110545A (en) 2020-11-19 2023-07-24 칼리버 임뮤노쎄라퓨틱스, 인크. Oncolytic immunotherapy by remodeling the tumor microenvironment
CN115044614B (en) * 2021-03-09 2023-10-20 上海目镜生物医药科技有限公司 Modified vector of AAV-8 serotype for gene targeting and expression, construction method and application thereof
US20240327866A1 (en) * 2021-07-21 2024-10-03 The Regents Of The University Of California Regulated viral delivery systems and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001650A (en) * 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US20020048805A1 (en) * 1998-01-16 2002-04-25 Julie C. Johnston Feline immunodeficiency virus gene therapy vectors

Also Published As

Publication number Publication date
WO2001091802A1 (en) 2001-12-06
US20060057553A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AU2001265187A1 (en) Chimeric viral vectors for gene therapy
AU2001291656A1 (en) Gene silencing vector
AU1152402A (en) Highly expressible genes
AU3358999A (en) Chimeric adenoviral vectors for targeted gene delivery
AU2001234981A1 (en) Adenoviral capsid containing chimeric protein ix
WO2003018621A8 (en) Genes
AU2003238456A1 (en) Viral vector
AU2002219841A1 (en) Vectors for conditional gene inactivation
AU769385C (en) Virus envelope vector for gene transfer
AU2001280576A1 (en) Tissue-specific self-inactivating gene therapy vector
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
AU2001238079A1 (en) Antibody gene therapy with adeno-associated viral vectors
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU6277600A (en) Novel chimeric genes
AU2001246703A1 (en) Dna immunization vectors
AU2001242625A1 (en) Gene sequence
AU2002337892A1 (en) Vectors for expressing multiple transgenes
AU2001264247A1 (en) GASC1 gene
AU2001288839A1 (en) Self-rearranging dna vectors
AU2001287976A1 (en) Chimeric vectors and their use for heterologous genes transfer
AU2001240103A1 (en) Reproduction-specific genes
AU2001247444A1 (en) Erbeta-mediated gene expression
GB0008966D0 (en) Vectors for gene therapy
AU2002254529A1 (en) Nucleic acids for transgene expression
AU2001285743A1 (en) Adipose-related gene